Finazzo M, Midiri M, Gallo C, Bartolotta T V, Luca A
Istituto di Radiologia P. Cignolini, Policlinico Universitario P. Giaccone, Palermo.
Radiol Med. 1998 Jun;95(6):599-607.
Superparamagnetic iron oxide (Spio) is a negative contrast material which is phagocytosed by reticuloendothelial cells. It significantly decreases the signal intensity of the organs where it is taken up selectively, especially on T2-weighted images. According to previous reports, it improves the visualization of focal liver lesions with(out) a low content of Kupffer's cells. We investigated the yield of Spio-enhanced MRI in the detection and characterization of focal liver lesions.
Eighteen patients underwent MRI before and after the administration of Spio particles. T1, PD, T2 SE and T2* GE images were acquired with a .5 T superconductive unit. The Spio dose was .075 mL/kg which was administered i.v. in 35-45 minutes' infusions. Images were acquired about 30-90 minutes after the end of administration. Scanning was repeated in one patient about 8 hours after the end of Spio administration.
Baseline MRI showed hepatocellular carcinoma (HCC) in 10 patients, metastases in 4, 1 dysplastic lesion, 1 single and 1 multiple hemangioma, 1 focal nodular hyperplasia (FNH) and 1 intrahepatic cholangiocarcinoma. No lesion was detected in one patient. Spio-enhanced MRI detected 7 more lesions that baseline MRI, with 11.47% sensitivity improvement. Moreover, Spio-enhanced MRI detected more lesions that baseline MRI in 5/18 patients (27.78%). PD/T2 SE images were the most sensitive ones, followed by T2* GE and finally by T1 SE. Nearly all HCC nodules (17/18), all metastatic lesions and the cholangiocarcinoma did not take up iron oxide and were relatively hyperintense to the liver. However, in one well-differentiated HCC, the nodule partially took up the contrast agent and became isointense, with high-signal borders on PD/T2 SE images. Both the dysplastic lesion and FNH took up iron oxide; the former was isointense to the liver, while the latter appeared slightly hyperintense, with a high-signal central scar. Finally, hemangiomas became hyperintense on Spio-enhanced T1 SE images and had slightly decreased signal intensity on Spio-enhanced T2 SE images.
In our experience iron oxide was an effective contrast material. Spio-enhanced MRI improved the detection and characterization of focal liver lesions relative to baseline MRI. Several liver-specific contrast agents are now available or in an advanced experimental stage. Therefore, future studies could be aimed at assessing the effectiveness of iron oxide versus other contrast agents and at establishing the role of Spio-enhanced MRI versus spiral CT and CT during arterial portography.
超顺磁性氧化铁(Spio)是一种阴性对比剂,可被网状内皮细胞吞噬。它能显著降低其选择性摄取部位器官的信号强度,尤其是在T2加权图像上。根据以往报道,它可改善库普弗细胞含量低的局灶性肝病变的可视化。我们研究了Spio增强MRI在局灶性肝病变检测和特征描述中的应用效果。
18例患者在注射Spio颗粒前后接受了MRI检查。使用0.5T超导单元采集T1、质子密度(PD)、T2自旋回波(SE)和T2*梯度回波(GE)图像。Spio剂量为0.075 mL/kg,通过静脉注射,在35 - 45分钟内输注完毕。在注射结束后约30 - 90分钟采集图像。在一名患者中,于Spio注射结束约8小时后重复扫描。
基线MRI显示10例肝细胞癌(HCC)、4例转移瘤、1例发育异常病变、1例单发和1例多发血管瘤、1例局灶性结节性增生(FNH)和1例肝内胆管癌。1例患者未检测到病变。Spio增强MRI比基线MRI多检测出7个病变,敏感性提高了11.47%。此外,在18例患者中有5例(27.78%)Spio增强MRI检测出的病变比基线MRI多。PD/T2 SE图像最敏感,其次是T2* GE图像,最后是T1 SE图像。几乎所有HCC结节(17/18)、所有转移瘤和胆管癌均未摄取氧化铁,相对于肝脏呈相对高信号。然而,在1例高分化HCC中,结节部分摄取对比剂并变为等信号,在PD/T2 SE图像上有高信号边界。发育异常病变和FNH均摄取了氧化铁;前者与肝脏等信号,而后者呈轻度高信号,有高信号中央瘢痕。最后,血管瘤在Spio增强T1 SE图像上变为高信号,在Spio增强T2 SE图像上信号强度略有降低。
根据我们的经验,氧化铁是一种有效的对比剂。Spio增强MRI相对于基线MRI改善了局灶性肝病变的检测和特征描述。目前有几种肝脏特异性对比剂可供使用或处于高级实验阶段。因此,未来的研究可以旨在评估氧化铁与其他对比剂的有效性,以及确定Spio增强MRI与螺旋CT和动脉门静脉造影CT相比的作用。